Bluejay Diagnostics, Inc. [Rocket]

In millions, except per share items	Dec-31-22	Dec-31-21	Dec-31-20	Dec-31-19
	10-K	10-K	10-K	S-1/A
Revenues [+]	0.2	0.0	0.0	0.5
Royalties				0.5
Net interest income		0.0	0.0
Revenue growth	3246.0%	210.6%	-99.5%
Cost of goods sold	0.2	0.0	0.0	1.6
Gross profit	0.0	0.0	0.0	-1.2
Gross margin	19.6%	0.0%	0.0%	-252.8%
Selling, general and administrative [+]	5.2	2.1	0.7	0.9
Sales and marketing	0.5	0.3	0.1
General and administrative	4.8	1.8	0.6	0.9
Research and development	4.2	1.1	0.5
Other operating expenses	0.2			-0.4
EBITDA [+]	-9.4	-3.1	-1.0	-1.5
EBITDA growth	204.7%	196.8%	-30.2%
EBITDA margin	-3773.9%	-41440.9%	-43378.6%	-321.8%
Depreciation and amortization	0.2	0.1	0.2	0.1
EBIT [+]	-9.6	-3.2	-1.2	-1.6
EBIT growth	195.8%	170.0%	-26.7%
EBIT margin	-3836.8%	-43398.7%	-49932.8%	-352.8%
Non-recurring items [+]	-0.2
Asset impairment	-0.2
Interest expense		0.4	0.0
Interest expense		0.4	0.0
Other income (expense), net [+]	0.0	0.1	0.1	0.8
Gain (loss) on debt retirement			0.1
Unrealized gain/loss on derivatives			0.0
Other	0.3	0.0	0.0
Pre-tax income	-9.3	-3.5	-1.2	-0.8
Income taxes	0.0	0.0	0.0	0.0
Tax rate	0.0%	0.0%	0.0%	0.0%
Net income	-9.3	-3.5	-1.2	-0.8
Net margin	-3733.1%	-46866.8%	-48342.4%	-177.3%

Basic EPS [+]	($0.46)	($0.41)	($0.37)	($0.26)
Growth	12.6%	11.2%	41.3%
Diluted EPS [+]	($0.46)	($0.41)	($0.37)	($0.26)
Growth	12.6%	11.2%	41.3%

Shares outstanding (basic) [+]	20.2	8.5	3.1	3.1
Growth	136.6%	170.8%	0.0%
Shares outstanding (diluted) [+]	20.2	8.5	3.1	3.1
Growth	136.6%	170.8%	0.0%

EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges.